Quarterly report pursuant to Section 13 or 15(d)

Financial Instruments

v3.24.2.u1
Financial Instruments
6 Months Ended
Jun. 30, 2024
Text Block [Abstract]  
Financial Instruments

Note 8 — Financial Instruments

Fair values have been determined for measurement and/or disclosure purposes based on the following methods. The Company characterizes inputs used in determining fair value using a hierarchy that prioritizes inputs depending on the degree to which they are observable. The levels of the fair value hierarchy are as follows:

Level 1 – fair value measurements are those derived from quoted prices (unadjusted) in active markets for identical assets or liabilities;
Level 2 – fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and
Level 3 – fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The carrying values of cash, receivables, payables and accrued liabilities approximate their fair values because of the short-term nature of these financial instruments. Balances due to and due from related parties have no terms and are payable on demand, thus are also considered current and short-term in nature, hence carrying value approximates fair value.

The component of the Company’s long-term debt attributed to the host liability is recorded at amortized cost. Investments in debt instruments that are held to maturity are also recorded at amortized cost.

The following table summarizes the fair value hierarchy for the Company’s financial assets and financial liabilities that are re-measured at their fair values periodically:

 

 

 

As of June 30, 2024

 

As of December 31, 2023

 

 

Level 1

 

Level 2

 

Level 3

 

Total

 

Level 1

 

Level 2

 

Level 3

 

Total

Financial assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Long term investments - other (1)

 

$

47

 

$

 

$

877

 

$

924

 

$

56

 

$

 

$

679

 

$

735

 

(1)
Long-term investments – other are included in the investments balance on the unaudited interim condensed consolidated balance sheets.

There were no transfers or change in valuation method between Level 1, Level 2, and Level 3 within the fair value hierarchy during the three and six months ended June 30, 2024 and 2023.

The Company’s investment in 4Front Venture Corp. as of June 30, 2024 and December 31, 2023, is considered to be a Level 1 instrument because it is comprised of shares of a public company, and there is an active market for the shares and observable market data available.

Level 1 investments are comprised of equity investments which are re-measured at fair value using quoted market prices.

Level 3 investments are comprised of two investments made by the Company in which it holds an equity interest. The Company exercises significant influence for one of these investments and therefore records this investment under the equity method. The investment was initially recognized at cost and the Company recognizes its proportionate share of earnings and losses from the investment each reporting period.

The following table summarizes the changes in Level 1 and Level 3 financial assets:

 

 

Financial Assets

 

 

 

4Front Venture Corp.

 

 

The Pharm Stand, LLC

 

 

Island Thyme, LLC

 

 

 

 

 

 

 

 

 

 

Balance as of December 31, 2023

 

$

56

 

$

 

$

679

Additions

 

 

 

 

125

 

 

195

Revaluations

 

 

(9)

 

 

 

 

Loss on equity method investments

 

 

 

 

 

 

(122)

Balance as of June 30, 2024

 

$

47

 

$

125

 

$

752

 

The Company’s financial and non-financial assets such as prepayments, other assets including equity accounted investments, property, plant and equipment, and intangibles, are measured at fair value when there is an indicator of impairment and are recorded at fair value only when an impairment charge is recognized.

The following table summarizes the Company’s long-term debt instruments (Note 4) at their carrying value and fair value:

 

 

As of June 30, 2024

 

As of December 31, 2023

 

 

Carrying Value

 

Fair Value

 

Carrying Value

 

Fair Value

June Unsecured Debentures

 

$

20,269

 

$

18,473

 

$

18,856

 

$

17,301

June Secured Debentures

 

 

137,337

 

 

124,457

 

 

130,103

 

 

118,118

Secured Notes

 

 

14,607

 

 

14,804

 

 

15,565

 

 

15,414

Other

 

 

725

 

 

732

 

 

752

 

 

772

Total

 

$

172,938

 

$

158,466

 

$

165,276

 

$

151,605